Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 17/20 | 0.59 |
| ▸ | ESR1 | P03372 | 7/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4452070 | 0.90 | LTA4H (0.44) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL28569320 | 0.88 | ESR2 (0.67) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL28542248 | 0.88 | ESR2 (0.67) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL5581754 | 0.88 | ESR2 (0.67) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL2095018 | 0.88 | ESR2 (0.67) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL698472 | 0.88 | ESR2 (0.67) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL698289 | 0.88 | ESR2 (0.67) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL28538819 | 0.88 | ESR2 (0.67) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL699003 | 0.88 | ESR2 (0.67) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL218897 | 0.88 | ESR2 (0.67) | ESR2ESR1CYP3A4CYP2C9CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822548-B2 | Compounds with activity at estrogen receptors | ACADIA PHARMACEUTICALS INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20110046237-A1 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ACADIA PHARMACEUTICALS INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-7825265-B2 | di-aromatic compounds for treatment and prevention of diseases and disorders related to estrogen receptors; 2-fluoro-1-methoxy-4-(1-phenyl-cyclohexyl)-benzene | ACADIA PHARMACEUTICALS INC. (US) | 2010-11-02 | — | — | US | disclosed |
| WO-2008033894-A2 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ACADIA PHARMACEUTICALS INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2007056500-A2 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ACADIA PHARMACEUTICALS INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| EP-1747182-A2 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTOR | Acadia Pharmaceuticals Inc. (US) | 2007-01-31 | — | — | EP | disclosed |
| US-20060122278-A1 | di-aromatic compounds for treatment and prevention of diseases and disorders related to estrogen receptors; 2-fluoro-1-methoxy-4-(1-phenyl-cyclohexyl)-benzene | ACADIA PHARMACEUTICALS INC. | 2006-06-08 | — | — | US | disclosed |
| US-20050256210-A1 | Compounds with activity at estrogen receptors | ACADIA PHARMACEUTICALS INC. | 2005-11-17 | — | — | US | disclosed |
| WO-2005108337-A2 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTOR | ACADIA PHARMACEUTICALS INC. (US) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122278-A1 | di-aromatic compounds for treatment and prevention of diseases and disorders related to estrogen receptors; 2-fluoro-1-methoxy-4-(1-phenyl-cyclohexyl)-benzene | GPER1, ESR1, ESR2 | ESR2 3/4885ESR1 2/4885CYP3A4 322/4885 |
| US-20110046237-A1 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ESR2, ESR1, GPER1 | ESR2 1/4885ESR1 2/4885CYP3A4 711/4885 |
| US-20050256210-A1 | Compounds with activity at estrogen receptors | ESR2, GPER1, ESRRG | ESR2 1/4885ESR1 4/4885CYP3A4 1488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.